AI new drug development specialist Syntekabio announced on the 8th that it will participate in 'BIO-Europe Spring 2024,' held in Barcelona, Spain, from the 18th to the 20th (local time).
BIO-Europe Spring is one of the world's largest biotech conferences. It is held twice a year in Europe, divided into spring and autumn events. Global pharmaceutical and biotech companies, as well as investors, attend to exchange industry information and actively discuss business cooperation.
Syntekabio will introduce its DDC (Deepmatcher® Drug Candidate) service, which includes an AI drug candidate factory-like platform and the LaunchPad service model. Centered on this, the company plans to meet with global pharmaceutical companies, biotech firms, and research institutions to discuss service contracts and cooperation plans.
The 'AI drug candidate factory-like platform' is an automated process that continuously advances the candidate development process using its proprietary AI platform 'Deepmatcher' and cloud infrastructure. It optimizes the candidate discovery process, enabling a reduction in the physical time required to generate new drug pipelines and improving resource efficiency.
The LaunchPad is a database of various stages of active substance data derived in advance for over 100 pre-selected target proteins. It allows new drug development to start from the active substance stage, accelerating the development speed for client companies. Additionally, since the discovery of active substances for desired targets is guaranteed, it lowers the entry barriers clients feel toward AI drug development.
The company plans to highlight the automated process that emphasizes the strengths of AI drug development, which can rapidly secure numerous substances targeting various diseases.
Jung Jong-sun, CEO of Syntekabio, said, "Clients are showing great interest," adding, "The automated process enables faster candidate discovery and development."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
